Proxorphan

Proxorphan
Clinical data
ATC code	none;
Identifiers
	IUPAC name 17-(cyclopropylmethyl)-6-oxamorphinan-3-ol; or; (1S,9R,10R)-17-(cyclopropylmethyl)-13-oxa-17-azatetracyclo[7.5.3.0~1,10~.0~2,7~]heptadeca-2,4,6-trien-4-ol;
CAS Number	69815-38-9;
ChemSpider	21476727;
UNII	TFE8T279QV;
CompTox Dashboard (EPA)	DTXSID90990082 ;
Chemical and physical data
Formula	C19H25NO2
Molar mass	299.41 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc2c(cc1O)C34CCN(C(C2)C3CCOC4)CC5CC5;

Proxorphan is an opioid analgesic and antitussive drug of the morphinan family that was never marketed.^[1] It acts as a κ-opioid receptor partial agonist and to a lesser extent as a μ-opioid receptor partial agonist.^[2]^[3]^[4]^[5]

References

^ David J. Triggle (1997). Dictionary of pharmacological agents. London: Chapman & Hall. ISBN 0-412-46630-9.
^ Leander JD (October 1983). "Further study of kappa opioids on increased urination". The Journal of Pharmacology and Experimental Therapeutics. 227 (1): 35–41. PMID 6137557.
^ Hayes AG, Birch PJ (August 1988). "Reversal by beta-funaltrexamine and 16-methyl cyprenorphine of the antinociceptive effects of opioid agonists in the mouse and guinea-pig". Neuropharmacology. 27 (8): 813–6. doi:10.1016/0028-3908(88)90096-2. PMID 3216959.
^ Picker MJ, Dykstra LA (May 1989). "Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists". The Journal of Pharmacology and Experimental Therapeutics. 249 (2): 557–66. PMID 2566680.
^ Picker MJ, Craft RM, Negus SS; et al. (November 1992). "Intermediate efficacy mu opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats". The Journal of Pharmacology and Experimental Therapeutics. 263 (2): 668–81. PMID 1331411. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)